Diabetes is a metabolic disorder that, during pregnancy, may affect fetal development. Fetal outcome depends on the type of diabetes present, the concentration of blood glucose and the extent of fetal exposure to elevated or frequently fluctuating glucose concentrations. The result of some diabetic pregnancies will be embryonic developmental abnormalities, a condition referred to as diabetic embryopathy. Tight glycemic control in type 1 diabetes during pregnancy using insulin therapy together with folic acid supplementation are partially able to prevent diabetic embryopathy; however, the protection is not complete and additional interventions are needed. Resveratrol, a polyphenol found largely in the skins of red grapes, is known to have antidiabetic action and is in clinical trials for the treatment of diabetes, insulin resistance, obesity and metabolic syndrome. Studies of resveratrol in a rodent model of diabetic embryopathy reveal that it significantly improves the embryonic outcome in terms of diminishing developmental abnormalities. Improvements in maternal and embryonic outcomes observed in rodent models may arise from resveratrol's antioxidative potential, antidiabetic action and antidyslipidemic nature. Whether resveratrol will have similar actions in human diabetic pregnancy is unknown. Here, we review the potential therapeutic use of resveratrol in diabetes and diabetic pregnancy.
PolonskyKS. The past 200 years in diabetes. N Eng J Med2012;367:1332–40
2.
EvensenAE. Update on gestational diabetes mellitus. Prim Care2012;39:83–94
3.
Centers for Disease Control and Prevention. National Diabetes Fact Sheet: National Estimates and General Information on Diabetes and Prediabetes in the United States, 2011. Atlanta, GA: US Department of Health and Human Services, Centers for Disease Control and Prevention, 2011
4.
BecerraJEKhouryMJCorderoJFEricksonJD. Diabetes mellitus during pregnancy and the risks for specific birth defects: a population-based case-control study. Pediatrics1990;85:1–9
5.
MillsJL. Malformations in infants of diabetic mothers. Teratology1982;25:385–94
6.
PhelanSAItoMLoekenMR. Neural tube defects in embryos of diabetic mice: role of the Pax-3 gene and apoptosis. Diabetes1997;46:1189–97
7.
CederbergJPicardJJErikssonUJ. Maternal diabetes in the rat impairs the formation of neural-crest derived cranial nerve ganglia in the offspring. Diabetologia2003;46:1245–51
8.
PedersenLMTygstrupIPedersenJ. Congenital malformations in newborn Infants of diabetic women. Correlation with maternal diabetic vascular complications. Lancet1964;1:1124–26
9.
ZhaoZReeceEA. Experimental mechanisms of diabetic embryopathy and strategies for developing therapeutic interventions. J Soc Gynecol Investig2005;12:549–57
10.
ErikssonUJCederbergJWentzelP. Congenital malformations in offspring of diabetic mothers – animal and human studies. Rev Endocr Metab Disord2003;4:79–93
11.
SalbaumJMKappenC. Neural tube defect genes and maternal diabetes during pregnancy. Birth Defects Res A Clin Mol Teratol2010;88:601–11
12.
OrnoyA. Embryonic oxidative stress as a mechanism of teratogenesis with special emphasis on diabetic embryopathy. Reprod Toxicol2007;24:31–41
13.
ZabihiSWentzelPErikssonUJ. Maternal blood glucose levels determine the severity of diabetic embryopathy in mice with different expression of copper-zinc superoxide dismutase (CuZnSOD). Toxicol Sci2008;105:166–72
14.
YangPZhaoZReeceEA. Involvement of c-Jun N-terminal kinases activation in diabetic embryopathy. Biochem Biophys Res Commun2007;357:749–54
15.
SolerNGWalshCHMalinsJM. Congenital malformations in infants of diabetic mothers. Q J Med1976;45:303–13
16.
ZabihiSLoekenMR. Understanding diabetic teratogenesis: where are we now and where are we going?Birth Defects Res A Clin Mol Teratol2010;88:779–90
17.
EversIMde ValkHWVisserGH. Risk of complications of pregnancy in women with type 1 diabetes: nationwide prospective study in the Netherlands. Br Med J2004;328:915
18.
SuhonenLHiilesmaaVTeramoK. Glycaemic control during early pregnancy and fetal malformations in women with type I diabetes mellitus. Diabetologia2000;43:79–82
19.
LoekenMR. Challenges in understanding diabetic embryopathy. Diabetes2008;57:3187–8
20.
MillsJLSignoreCC. Folic acid and the prevention of neural-tube defects. N Engl J Med2004;350:2209–11
21.
GareskogMErikssonUJWentzelP. Combined supplementation of folic acid and vitamin E diminishes diabetes-induced embryotoxicity in rats. Birth Defects Res A Clin Mol Teratol2006;76:483–90
22.
WentzelPGareskogMErikssonUJ. Folic acid supplementation diminishes diabetes- and glucose-induced dysmorphogenesis in rat embryos in vivo and in vitro. Diabetes2005;54:546–53
23.
MillsJLSignoreC. Neural tube defect rates before and after food fortification with folic acid. Birth Defects Res A Clin Mol Teratol2004;70:844–45
24.
WolffTWitkopCTMillerTSyedSB. Folic acid supplementation for the prevention of neural tube defects: an update of the evidence for the US Preventive Services Task Force. Ann Intern Med2009;150:632–39
25.
BanhidyFAcsNPuhoEHCzeizelAE. Congenital abnormalities in the offspring of pregnant women with type 1, type 2 and gestational diabetes mellitus: a population-based case-control study. Congenit Anom (Kyoto)2010;50:115–21
26.
WilsonRDDaviesGDesiletsVReidGJSummersAWyattPYoungD. The use of folic acid for the prevention of neural tube defects and other congenital anomalies. J Obstet Gynaecol Can2003;25:959–73
27.
KimKCFrisoSChoiSW. DNA methylation, an epigenetic mechanism connecting folate to healthy embryonic development and aging. J Nutr Biochem2009;20:917–26
28.
RogersEJ. Has enhanced folate status during pregnancy altered natural selection and possibly Autism prevalence? A closer look at a possible link. Med Hypotheses2008;71:406–10
29.
CallejonGMayor-OleaAJimenezAJGaitanMJPalomaresARMartinezFRuizMReyes-EngelA. Genotypes of the C677T and A1298C polymorphisms of the MTHFR gene as a cause of human spontaneous embryo loss. Hum Reprod2007;22:3249–54
30.
DoGMJungUJParkHJKwonEYJeonSMMcGregorRAChoiMS. Resveratrol ameliorates diabetes-related metabolic changes via activation of AMP-activated protein kinase and its downstream targets in db/db mice. Mol Nutr Food Res2012;56:1282–91
31.
SinghCKKumarAHitchcockDBFanDGoodwinRLavoieHANagarkattiPDipetteDJSinghUS. Resveratrol prevents embryonic oxidative stress and apoptosis associated with diabetic embryopathy and improves glucose and lipid profile of diabetic dam. Mol Nutr Food Res2011;55:1186–96
32.
YangFZhangTItoY. Large-scale separation of resveratrol, anthraglycoside A and anthraglycoside B from Polygonum cuspidatum Sieb. et Zucc by high-speed counter-current chromatography. J Chromatogr A2001;919:443–48
33.
MagyarKHalmosiRPalfiAFeherGCzopfLFulopABattyanyISumegiBTothKSzabadosE. Cardioprotection by resveratrol: a human clinical trial in patients with stable coronary artery disease. Clin Hemorheol Microcirc2012;50:179–87
34.
BishayeeAPolitisTDarveshAS. Resveratrol in the chemoprevention and treatment of hepatocellular carcinoma. Cancer Treat Rev2010;36:43–53
35.
FuldaS. Resveratrol and derivatives for the prevention and treatment of cancer. Drug Discov Today2010;15:757–65
36.
HowitzKTBittermanKJCohenHYLammingDWLavuSWoodJGZipkinREChungPKisielewskiAZhangLLSchererBSinclairDA. Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan. Nature2003;425:191–96
37.
ValenzanoDRCellerinoA. Resveratrol and the pharmacology of aging: a new vertebrate model to validate an old molecule. Cell Cycle2006;5:1027–32
38.
PaulBMasihIDeopujariJCharpentierC. Occurrence of resveratrol and pterostilbene in age-old darakchasava, an ayurvedic medicine from India. J Ethnopharmacol1999;68:71–76
39.
RamadoriGGautronLFujikawaTViannaCRElmquistJKCoppariR. Central administration of resveratrol improves diet-induced diabetes. Endocrinology2009;150:5326–33
40.
MilneJCLambertPDSchenkSCarneyDPSmithJJGagneDJJinLBossOPerniRBVuCBBemisJEXieRDischJSNgPYNunesJJLynchAVYangHGalonekHIsraelianKChoyWIfflandALavuSMedvedikOSinclairDAOlefskyJMJirousekMRElliottPJWestphalCH. Small molecule activators of SIRT1 as therapeutics for the treatment of type 2 diabetes. Nature2007;450:712–16
41.
SharmaSMisraCSArumugamSRoySShahVDavisJAShirumallaRKRayA. Antidiabetic activity of resveratrol, a known SIRT1 activator in a genetic model for type-2 diabetes. Phytother Res2011;25:67–73
42.
PalsamyPSubramanianS. Resveratrol, a natural phytoalexin, normalizes hyperglycemia in streptozotocin-nicotinamide induced experimental diabetic rats. Biomed Pharmacother2008;62:598–605
43.
BaurJAPearsonKJPriceNLJamiesonHALerinCKalraAPrabhuVVAllardJSLopez-LluchGLewisKPistellPJPoosalaSBeckerKGBossOGwinnDWangMRamaswamySFishbeinKWSpencerRGLakattaEGLe CouteurDShawRJNavasPPuigserverPIngramDKde CaboRSinclairDA. Resveratrol improves health and survival of mice on a high-calorie diet. Nature2006;444:337–42
44.
UmJHParkSJKangHYangSForetzMMcBurneyMWKimMKViolletBChungJH. AMP-activated protein kinase-deficient mice are resistant to the metabolic effects of resveratrol. Diabetes2010;59:554–63
45.
CottartCHNivet-AntoineVLaguillier-MorizotCBeaudeuxJL. Resveratrol bioavailability and toxicity in humans. Mol Nutr Food Res2010;54:7–16
46.
WalleTHsiehFDeLeggeMHOatisJEJrWalleUK. High absorption but very low bioavailability of oral resveratrol in humans. Drug Metab Dispos2004;32:1377–82
47.
Vaz-da-SilvaMLoureiroAIFalcaoANunesTRochaJFFernandes-LopesCSoaresEWrightLAlmeidaLSoares-da-SilvaP. Effect of food on the pharmacokinetic profile of trans-resveratrol. Int J Clin Pharmacol Ther2008;46:564–70
48.
HowellsLMBerryDPElliottPJJacobsonEWHoffmannEHegartyBBrownKStewardWPGescherAJ. Phase I randomized, double-blind pilot study of micronized resveratrol (SRT501) in patients with hepatic metastases – safety, pharmacokinetics, and pharmacodynamics. Cancer Prevention Res2011;4:1419–25
49.
NarayananNKNargiDRandolphCNarayananBA. Liposome encapsulation of curcumin and resveratrol in combination reduces prostate cancer incidence in PTEN knockout mice. Int J Cancer2009;125:1–8
50.
JohnsonJJNihalMSiddiquiIAScarlettCOBaileyHHMukhtarHAhmadN. Enhancing the bioavailability of resveratrol by combining it with piperine. Mol Nutr Food Res2011;55:1169–76
51.
PatelKRScottEBrownVAGescherAJStewardWPBrownK. Clinical trials of resveratrol. Ann NY Acad Sci2011;1215:161–69
52.
SmoligaJMBaurJAHausenblasHA. Resveratrol and health – a comprehensive review of human clinical trials. Mol Nutr Food Res2011;55:1129–41
53.
FujitakaKOtaniHJoFJoHNomuraEIwasakiMNishikawaMIwasakaTDasDK. Modified resveratrol Longevinex improves endothelial function in adults with metabolic syndrome receiving standard treatment. Nutr Res2011;31:842–47
54.
ZhangHZhangJUngvariZZhangC. Resveratrol improves endothelial function: role of TNF-α and vascular oxidative stress. Arterioscler Thromb Vasc Biol2009;29:1164–71
55.
PenumathsaSVThirunavukkarasuMZhanLMaulikGMenonVPBagchiDMaulikN. Resveratrol enhances GLUT-4 translocation to the caveolar lipid raft fractions through AMPK/Akt/eNOS signalling pathway in diabetic myocardium. J Cell Mol Med2008;12:2350–61
56.
HerreraEOrtega-SenovillaH. Disturbances in lipid metabolism in diabetic pregnancy – Are these the cause of the problem?Best Pract Res Clin Endocrinol Metab2010;24:515–25
57.
ChoIJAhnJYKimSChoiMSHaTY. Resveratrol attenuates the expression of HMG-CoA reductase mRNA in hamsters. Biochem Biophys Res Commun2008;367:190–94
58.
OforiBReyEBerardA. Risk of congenital anomalies in pregnant users of statin drugs. Br J Clin Pharmacol2007;64:496–509
59.
Statins: beware during pregnancy. Prescrire Int2006;15:18–19
60.
DengJYHsiehPSHuangJPLuLSHungLM. Activation of estrogen receptor is crucial for resveratrol-stimulating muscular glucose uptake via both insulin-dependent and -independent pathways. Diabetes2008;57:1814–23
61.
ShearerGCJolesJAJonesHWalzemRLKaysenGA. Estrogen effects on triglyceride metabolism in analbuminemic rats. Kidney Int2000;57:2268–74
62.
BaslyJPMarre-FournierFLe BailJCHabriouxGChuliaAJ. Estrogenic/antiestrogenic and scavenging properties of (E)- and (Z)-resveratrol. Life Sci2000;66:769–77
63.
GehmBDMcAndrewsJMChienPYJamesonJL. Resveratrol, a polyphenolic compound found in grapes and wine, is an agonist for the estrogen receptor. Proc Natl Acad Sci USA1997;94:14138–43
64.
JangJYParkDShinSJeonJHChoiBIJooSSHwangSYNahmSSKimYB. Antiteratogenic effect of resveratrol in mice exposed in utero to 2,3,7,8-tetrachlorodibenzo-p-dioxin. Eur J Pharmacol2008;591:280–83
65.
SinghNPSinghUSNagarkattiMNagarkattiPS. Resveratrol (3,5,4′-trihydroxystilbene) protects pregnant mother and fetus from the immunotoxic effects of 2,3,7,8-tetrachlorodibenzo-p-dioxin. Mol Nutr Food Res2011;55:209–19
66.
WilliamsLDBurdockGAEdwardsJABeckMBauschJ. Safety studies conducted on high-purity trans-resveratrol in experimental animals. Food Chem Toxicol2009;47:2170–82
67.
PatelKRBrownVAJonesDJBrittonRGHemingwayDMillerASWestKPBoothTDPerloffMCrowellJABrennerDEStewardWPGescherAJBrownK. Clinical pharmacology of resveratrol and its metabolites in colorectal cancer patients. Cancer Res2010;70:7392–99
68.
KumarASinghCKLaVoieHADipetteDJSinghUS. Resveratrol restores Nrf2 level and prevents ethanol-induced toxic effects in the cerebellum of a rodent model of fetal alcohol spectrum disorders. Mol Pharmacol2011;80:446–57
69.
NielsenGLNorgardBPuhoERothmanKJSorensenHTCzeizelAE. Risk of specific congenital abnormalities in offspring of women with diabetes. Diabet Med2005;22:693–96
70.
ReeceEAWuYK. Prevention of diabetic embryopathy in offspring of diabetic rats with use of a cocktail of deficient substrates and an antioxidant. Am J Obstet Gynecol1997;176:790–97
71.
ZabihiSWentzelPErikssonUJ. Altered uterine perfusion is involved in fetal outcome of diabetic rats. Placenta2008;29:413–21
72.
WangQXuJRottinghausGESimonyiALubahnDSunGYSunAY. Resveratrol protects against global cerebral ischemic injury in gerbils. Brain Res2002;958:439–47
73.
MokniMElkahouiSLimamFAmriMAouaniE. Effect of resveratrol on antioxidant enzyme activities in the brain of healthy rat. Neurochem Res2007;32:981–87
74.
AtesOCayliSRYucelNAltinozEKocakADurakMATurkozYYologluS. Central nervous system protection by resveratrol in streptozotocin-induced diabetic rats. J Clin Neurosci2007;14:256–60
75.
VenturiniCDMerloSSoutoAAFernandes MdaCGomezRRhodenCR. Resveratrol and red wine function as antioxidants in the nervous system without cellular proliferative effects during experimental diabetes. Oxid Med Cell Longev2010;3:434–41
OngWYLuXRHuCYHalliwellB. Distribution of hydroxynonenal-modified proteins in the kainate-lesioned rat hippocampus: evidence that hydroxynonenal formation precedes neuronal cell death. Free Radic Biol Med2000;28:1214–21
78.
Etienne-MannevilleSHallA. Rho GTPases in cell biology. Nature2002;420:629–35
79.
SinghUSKunarMTKaoYLBakerKM. Role of transglutaminase II in retinoic acid-induced activation of RhoA- associated kinase-2. Embo J2001;20:2413–23
80.
SinghUSPanJKaoYLJoshiSYoungKLBakerKM. Tissue transglutaminase mediates activation of RhoA and MAP kinase pathways during retinoic acid-induced neuronal differentiation of SH-SY5Y cells. J Biol Chem2003;278:391–99
81.
NobesCDHawkinsPStephensLHallA. Activation of the small GTP-binding proteins rho and rac by growth factor receptors. J Cell Sci1995;108(Part 1):225–33
82.
PanJKaoYLJoshiSJeetendranSDipetteDSinghUS. Activation of Rac1 by phosphatidylinositol 3-kinase in vivo: role in activation of mitogen-activated protein kinase (MAPK) pathways and retinoic acid-induced neuronal differentiation of SH-SY5Y cells. J Neurochem2005;93:571–83
83.
ScitaGTencaPFrittoliETocchettiAInnocentiMGiardinaGDi FiorePP. Signaling from Ras to Rac and beyond: not just a matter of GEFs. EMBO J2000;19:2393–98
84.
SprangSR. G proteins, effectors and GAPs: structure and mechanism. Curr Opin Struct Biol1997;7:849–56
85.
HartMJMaruYLeonardDWitteONEvansTCerioneRA. A GDP dissociation inhibitor that serves as a GTPase inhibitor for the Ras-like protein CDC42Hs. Science1992;258:812–15
86.
BrounsMRMathesonSFHuKQDelalleICavinessVSSilverJBronsonRTSettlemanJ. The adhesion signaling molecule p190 RhoGAP is required for morphogenetic processes in neural development. Development2000;127:4891–903
87.
Ybot-GonzalezPSaveryDGerrelliDSignoreMMitchellCEFauxCHGreeneNDCoppAJ. Convergent extension, planar-cell-polarity signalling and initiation of mouse neural tube closure. Development2007;134:789–99
88.
LindqvistMHornZBryjaVSchulteGPapachristouPAjimaRDybergCArenasEYamaguchiTPLagercrantzHRingstedtT. Vang-like protein 2 and Rac1 interact to regulate adherens junctions. J Cell Sci2010;123:472–83
89.
SuzukiMMoritaHUenoN. Molecular mechanisms of cell shape changes that contribute to vertebrate neural tube closure. Dev Growth Differ2012;54:266–76
90.
KinoshitaNSasaiNMisakiKYonemuraS. Apical accumulation of Rho in the neural plate is important for neural plate cell shape change and neural tube formation. Mol Biol Cell2008;19:2289–99
91.
CamererEBarkerADuongDNGanesanRKataokaHCornelissenIDarraghMRHussainAZhengYWSrinivasanYBrownCXuSMRegardJBLinCYCraikCSKirchhoferDCoughlinSR. Local protease signaling contributes to neural tube closure in the mouse embryo. Dev Cell2010;18:25–38
92.
JalinkKvan CorvenEJHengeveldTMoriiNNarumiyaSMoolenaarWH. Inhibition of lysophosphatidate- and thrombin-induced neurite retraction and neuronal cell rounding by ADP ribosylation of the small GTP-binding protein Rho. J Cell Biol1994;126:801–10
93.
KozmaRSarnerSAhmedSLimL. Rho family GTPases and neuronal growth cone remodelling: relationship between increased complexity induced by Cdc42Hs, Rac1, and acetylcholine and collapse induced by RhoA and lysophosphatidic acid. Mol Cell Biol1997;17:1201–11
94.
LeeuwenFNKainHEKammenRAMichielsFKranenburgOWCollardJG. The guanine nucleotide exchange factor Tiam1 affects neuronal morphology; opposing roles for the small GTPases Rac and Rho. J Cell Biol1997;139:797–807
95.
FukazawaYSaitohYOzawaFOhtaYMizunoKInokuchiK. Hippocampal LTP is accompanied by enhanced F-actin content within the dendritic spine that is essential for late LTP maintenance in vivo. Neuron2003;38:447–60
96.
ZitoKKnottGShepherdGMShenolikarSSvobodaK. Induction of spine growth and synapse formation by regulation of the spine actin cytoskeleton. Neuron2004;44:321–34
97.
LuoL. Rho GTPases in neuronal morphogenesis. Nat Rev Neurosci2000;1:173–80
98.
LuoL. Actin cytoskeleton regulation in neuronal morphogenesis and structural plasticity. Annu Rev Cell Dev Biol2002;18:601–35
99.
DianaGValentiniGTravaglioneSFalzanoLPieriMZonaCMeschiniSFabbriAFiorentiniC. Enhancement of learning and memory after activation of cerebral Rho GTPases. Proc Natl Acad Sci USA2007;104:636–41
100.
RamakersGJ. Rho proteins, mental retardation and the cellular basis of cognition. Trends Neurosci2002;25:191–99
101.
SinWCChenXQLeungTLimL. RhoA-binding kinase alpha translocation is facilitated by the collapse of the vimentin intermediate filament network. Mol Cell Biol1998;18:6325–39
102.
AghajanianAWittchenESCampbellSLBurridgeK. Direct activation of RhoA by reactive oxygen species requires a redox-sensitive motif. PLoS One2009;4:e8045
MarkMGhyselinckNBChambonP. Function of retinoic acid receptors during embryonic development. Nucl Recept Signal2009;7:e002
105.
WilsonLGaleEMadenM. The role of retinoic acid in the morphogenesis of the neural tube. J Anat2003;203:357–68
106.
LiNSunSWangDYaoPYangXYanHDuYYingCLiuL. Suppression of retinoic acid receptors may contribute to embryonic skeleton hypoplasia in maternal rats with chronic vitamin A deficiency. J Nutr Biochem2010;21:710–16
107.
ChenWHMorriss-KayGMCoppAJ. Genesis and prevention of spinal neural tube defects in the curly tail mutant mouse: involvement of retinoic acid and its nuclear receptors RAR-beta and RAR-gamma. Development1995;121:681–91
108.
LenhardJM. PPAR gamma/RXR as a molecular target for diabetes. Recept Channel2001;7:249–58
109.
SinghCKKumarALaVoieHADipetteDJSinghUS. Resveratrol prevents impairment in activation of retinoic acid receptors and MAP kinases in the embryos of a rodent model of diabetic embryopathy. Reprod Sci2012;19:949–61
110.
YanJHalesBF. p38 and c-Jun N-terminal kinase mitogen-activated protein kinase signaling pathways play distinct roles in the response of organogenesis-stage embryos to a teratogen. J Pharmacol Exp Ther2008;326:764–72
111.
TorresMFormanHJ. Redox signaling and the MAP kinase pathways. Biofactors2003;17:287–96
112.
MalemudCJ. Inhibitors of stress-activated protein/mitogen-activated protein kinase pathways. Curr Opin Pharmacol2007;7:339–43
